Study finds prediabetes remission possible without weight loss

New research published in Nature Medicine reveals that people with prediabetes can normalize blood sugar levels without losing weight. About one in four participants in lifestyle programs achieved this remission, offering protection against diabetes similar to weight loss methods. The key factors involve fat distribution and certain hormones.

For decades, advice for those with prediabetes—a condition affecting up to one in three adults, depending on age—has centered on weight loss to prevent diabetes. Yet diabetes rates continue to rise globally, and many struggle to meet weight targets. A study challenges this by showing prediabetes remission without weight reduction is feasible and equally protective against type 2 diabetes. In the research, published in Nature Medicine (2025; 31(10):3330, DOI: 10.1038/s41591-025-03944-9), approximately one in four individuals in lifestyle interventions normalized blood sugar without shedding pounds, and sometimes even with weight gain. The explanation lies in fat storage. Visceral fat, deep in the abdomen around organs, drives inflammation and impairs insulin function, raising blood glucose. Subcutaneous fat under the skin, however, aids metabolism by releasing supportive hormones. Participants achieving remission shifted fat from visceral to subcutaneous areas. Hormones also play a role, particularly GLP-1-like ones, which enhance insulin release from pancreatic beta cells when glucose rises. Those in remission boosted these naturally while curbing glucose-raising hormones—similar to effects from drugs like Wegovy and Mounjaro. Practical steps include diets rich in polyunsaturated fatty acids, such as Mediterranean-style with fish oil, olives, and nuts, which reduce visceral fat. Endurance exercise similarly targets abdominal fat without necessitating overall weight drop. While weight loss remains beneficial for health, the study urges prioritizing blood sugar normalization and metabolic shifts. Authors from University of Tübingen, including Andreas L. Birkenfeld and Reiner Jumpertz-von Schwartzenberg, suggest doctors track these changes for patients facing weight loss difficulties. This approach could broaden diabetes prevention worldwide.

Relaterede artikler

Pediatrician assessing overweight children in clinic, highlighting study-recommended early treatment to prevent adult risks like diabetes and hypertension.
Billede genereret af AI

Studie anbefaler behandling til alle børn med svær overvægt

Rapporteret af AI Billede genereret af AI

Et nyt studie fra Karolinska Institutet viser, at børn med moderat overvægt har en højere risiko for type 2-diabetes, forhøjet blodtryk og forstyrrelser i fedtstofferne i voksenlivet, selv uden tydelige risikomarkører. Forskerne opfordrer til behandling af alle børn i denne gruppe.

Weight loss reversed obesity-related glucose problems in both young and mid-aged mice, but researchers at Ben-Gurion University of the Negev report that, in mid-aged animals, early weight loss coincided with a temporary rise in inflammation-related changes in the hypothalamus, a brain region involved in appetite and energy regulation.

Rapporteret af AI

A low-fat vegan diet has shown promise in helping people with type 1 diabetes cut their daily insulin needs by nearly 30%, according to new research. The study, published in BMC Nutrition, found that participants on this plant-based plan also saved on insulin costs without restricting calories or carbohydrates. In contrast, those following a portion-controlled diet saw no significant changes.

Researchers have identified why living at high altitudes reduces diabetes risk: red blood cells absorb excess glucose in low-oxygen conditions. This metabolic shift lowers blood sugar levels, as shown in mouse experiments. A new drug mimicking this effect reversed diabetes in mice, suggesting potential treatments.

Rapporteret af AI Faktatjekket

Researchers at Karolinska Institutet and Stockholm University have developed an experimental oral drug that boosts metabolism in skeletal muscle, improving blood sugar control and fat burning in early studies without reducing appetite or muscle mass. Unlike GLP-1-based drugs such as Ozempic, the candidate acts directly on muscle tissue and has shown good tolerability in an initial clinical trial, according to the study authors.

Three new Cochrane reviews conclude that tirzepatide, semaglutide and liraglutide produce clinically meaningful weight loss in adults with obesity, while evidence on long‑term safety, broader outcomes and equitable access remains limited. The findings will inform forthcoming World Health Organization guidance on obesity treatment.

Rapporteret af AI Faktatjekket

Researchers working at Harvard University and collaborators in Brazil have identified metabolites produced by gut bacteria that travel through the portal vein to the liver and appear to influence energy use and insulin sensitivity in mice. The findings, published in Cell Metabolism, suggest possible new strategies for preventing or treating obesity and type 2 diabetes by targeting gut–liver communication.([sciencedaily.com](https://www.sciencedaily.com/releases/2025/12/251214100926.htm?utm_source=openai))

 

 

 

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis